Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- President Tamura Says Nichi-Iko to Stop Receiving Marketing Right Transfers of Long-Listed Products
January 16, 2012
- Market for New Oral Anticoagulants Getting Crowded
January 16, 2012
- Sales of DPP-4 Inhibitors on Track to Reach ¥100 Bil. this Fiscal Year
January 16, 2012
- With 3 New Treatments, 2011 a Big Year for Domestic AD Market
January 16, 2012
- No Clear Road to Distribution Reform; New Drug Premium Hurting Wholesalers’ Business
January 16, 2012
- Research Oriented-companies Shake Up Generics Market with Established Products
January 16, 2012
- Taiyo to Be Core of Teva’s Operations in Japan
January 16, 2012
- Nichi-Iko Will Soon Decide on Independent or Joint PI Trial for Remicade Biosimilar: President Tamura
January 16, 2012
- Otsuka to Focus on CNS Field, Ending Collaboration in Immunology, Inflammation with UCB
January 16, 2012
- With 3 New Treatments, 2011 a Big Year for Domestic AD Market
January 15, 2012
- Nichi-Iko Posts Record-High Sales, Profits in FY2011
January 13, 2012
- Pfizer to Strengthen Role of Manufacturing Division by Spin-Off, Utilizing Its Formulation Technology
January 13, 2012
- Hisamitsu: Sales Up 1.2% Due to Favorable Performance of Overseas Subsidiaries
January 13, 2012
- Major Dispensing Pharmacies, Intermediary Companies Aggressively Seek M&A
January 12, 2012
- Survey Shows Astellas Website Most Frequently Accessed by Doctors
January 12, 2012
- Barclays Capital Report Mentions Tivozanib, Raises Astellas Pharma’s Target Stock Price
January 12, 2012
- Interprotein, Takeda Sign Collaboration Agreement on Molecular Design for PPI Modulators
January 12, 2012
- Sales of Ethical Drugs Up 5.2% in November: Crecon Report
January 12, 2012
- Administration of OTSA101 Started in Trial for Synovial Sarcoma: OncoTherapy
January 12, 2012
- Dispensing Point Services Should Continue: Mr Arai of Sugi HD
January 12, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…